Abstract
Background: Oral multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (IO), have increased survival of patients with metastatic renal cell carcinoma (mRCC). Common sites of mRCC are lymph nodes, lung, liver and bone, but some unexpected clinical presentations sometime occurred as cardiac metastasis without validated treatment. We described a case report of a patient presenting cardiac metastasis treated with IO who showed a dramatic, durable response, which was prolonged despite stopping the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
